为什么 OpenEvidence 走不进中国临床?轻松健康推出本土“循证智能体流”

财闻
Mar 11

随着医疗智能工具在全球范围内加速落地,行业正在形成一个越来越清晰的判断:医疗 AI 的价值,已经不再只取决于“会不会回答”,而更取决于“能不能进入真实临床流程”。在这一范式转移下,全球医疗 AI 正逐渐分化出三条具有代表性的技术路径:以 OpenEvidence 为代表的“循证检索流”,以通用大模型为基础的“生成增强流”,以及以轻松健康“证元芳”为代表的“循证智能体流”。2026年3月9日,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10